查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1700110

2032 年骨質疏鬆症藥物市場預測：按藥物類別、給藥途徑、分銷管道、最終用戶和地區進行的全球分析

Osteoporosis Drugs Market Forecasts to 2032 - Global Analysis by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), Calcitonin and Other Drug Classes), Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球骨質疏鬆症藥物市場預計在 2025 年達到 163 億美元，到 2032 年將達到 238 億美元，預測期內的複合年成長率為 5.5%。

骨質疏鬆症藥物是用來預防、治療和控制骨質疏鬆症的藥物。骨質疏鬆症藥物透過減緩骨質流失（抗吸收藥物）或促進骨形成（合成代謝藥物）發揮作用。常見的選擇包括雙磷酸鹽、選擇性雌激素受體調節(SERM)、抑鈣素、副甲狀腺素類似物和單株抗體。這些藥物有助於降低骨折風險、提高骨骼密度和維持骨骼強度。骨質疏鬆症藥物是根據年齡、性別、骨折史和骨骼密度等因素開出的，通常與鈣、維生素 D 和生活方式的改變結合使用，以達到最佳骨骼健康和預防骨折。

老年人口不斷增加

老年人口的增加是骨質疏鬆症藥物市場成長的主要驅動力。隨著老齡化的成長，骨骼密度會降低，骨質疏鬆症的可能性也會增加，因此對有效治療的需求也越來越大。隨著老年人獲得醫療保健的機會和對醫療保健的了解不斷增加，市場正在不斷擴大。此外，改良的藥物配方和客製化的治療方法可以滿足老年人的特殊需求。隨著政府和醫療保健提供者越來越重視骨骼健康，預計市場將穩步擴大，這將為患者和製藥公司帶來利益。

骨質疏鬆症藥物高成本

骨質疏鬆症藥物的高價格限制了患者獲得治療的機會和堅持治療，嚴重阻礙了市場的成長。許多患者，尤其是中低收入地區的患者，承受經濟負擔，導致需求減少，疾病負擔增加。此外，高價格對醫療預算和保險系統造成壓力，阻礙了其廣泛採用。這些經濟障礙限制了市場擴張，減緩了創新的採用，並迫使患者尋求替代或效果較差的治療方法。

藥物研發進展

隨著療效和安全性提高的創新治療方法的推出，藥物開發的進步極大地推動了骨質疏鬆症藥物市場的發展。生物製藥、單株抗體和新型療法的突破性進展正在改善患者的治療效果、降低骨折風險並提高骨骼密度。標靶治療和個人化醫療的前沿研究正在擴大市場潛力。此外，下一代骨質疏鬆症藥物的監管核准和研發投入的增加正在加速市場成長，為全球數百萬骨質疏鬆症患者帶來新的希望。

副作用和安全問題

副作用和安全問題是骨質疏鬆症藥物市場成長的主要障礙。胃腸不適、心血管風險和非典型骨折等副作用會妨礙患者的依從性和醫生的處方。安全警告和監管審查可能會進一步限制藥物的採用並影響銷售。負面宣傳和訴訟也會削弱消費者信心。這些挑戰推動了對替代療法的需求，限制了市場擴張並影響了製藥公司的收益來源。

COVID-19的影響：

由於醫療機構關閉和患者就診次數減少，COVID-19 疫情導致診斷和治療延遲，擾亂了骨質疏鬆症藥物市場。供應鏈中斷影響了藥品的可得性，經濟的不確定性限制了病患的負擔能力。然而，遠端醫療的興起和停工期間人們對骨骼健康的認知的提高幫助市場復甦。疫情過後，隨著醫療服務的恢復，市場復甦，骨質疏鬆症治療的需求增加。

預計預測期內副甲狀腺素(PTH) 類似物部分將佔最大佔有率。

副甲狀腺素(PTH) 類似物預計將在預測期內佔據最大的市場佔有率，因為它具有減緩骨質流失和促進骨形成的能力。這些藥物，如特立帕肽和阿巴洛帕肽，對骨折風險高的患者特別有益，可以增加骨骼密度並降低骨折風險。意識的增強、骨質疏鬆症盛行率的上升以及有利的報銷政策進一步推動了需求。此外，藥物輸送系統的持續研發努力和技術進步正在提升市場佔有率。

預計在預測期內，醫院部門的複合年成長率最高。

預計醫院部門在預測期內將出現最高的成長率。這是因為醫院提供骨骼密度掃描等先進的診斷工具，以促進早期發現和個人化治療計劃。此外，專業醫療保健專業人員加強病患教育和藥物依從性以改善治療效果。骨質疏鬆症盛行率的不斷上升，加上醫院提供全面照護的能力不斷下降，導致藥物需求不斷增加。此外，與製藥公司的合作支持研究和創新，進一步促進市場成長。

佔比最大的地區：

在預測期內，由於配方的進步，預計北美將佔據最大的市場佔有率。意識的提高、政府的措施以及醫療保健服務的改善將進一步推動市場擴張。製藥公司正在利用生技藥品和合成代謝療法進行創新，以改善患者的治療效果。該市場透過降低骨折風險和提高生活品質對公眾健康產生了積極影響。透過持續的研究發展和策略合作，該領域推動醫學進步，為患者和醫療保健系統帶來長期利益。

複合年成長率最高的地區：

在預測期內，由於醫療保健投資的增加，預計亞太地區將呈現最高的複合年成長率。政府和醫療保健提供者將骨質疏鬆症管理放在首位，從而增加了獲得先進治療的機會。藥物配方的創新和生技藥品的採用正在改善患者的治療效果。此外，生活方式的改變和都市化也增加了骨質疏鬆症的盛行率，進一步推動了需求。擴大這些市場將刺激全部區域的經濟成長、創造就業機會和製藥研究的進步。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章 全球骨質疏鬆症藥物市場（依藥物類別）

  • 雙磷酸鹽
    • 阿崙膦酸鈉
    • 利塞膦酸鹽
  • 選擇性雌激素受體調節（SERM）
  • 副甲狀腺素相關蛋白（PTHrP）類似物
  • 副甲狀腺素（PTH）類似物
  • RANK配體（RANKL）抑制劑
  • 抑鈣素
  • 其他藥物類別

第6章 全球骨質疏鬆症藥物市場（依給藥途徑）

  • 口服
  • 注射

第7章 全球骨質疏鬆症藥物市場（按分銷管道）

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第8章全球骨質疏鬆症藥物市場（按最終用戶）

  • 醫院
  • 診所
  • 居家照護

第9章 全球骨質疏鬆症藥物市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Radius Health, Inc.
  • UCB SA
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Cipla Inc.
  • Daiichi Sankyo Company
  • Novo Nordisk A/S
  • Sun Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Sanofi
  • Bristol-Myers Squibb Company
Product Code: SMRC29013

According to Stratistics MRC, the Global Osteoporosis Drugs Market is accounted for $16.3 billion in 2025 and is expected to reach $23.8 billion by 2032 growing at a CAGR of 5.5% during the forecast period. Osteoporosis drugs are medications designed to prevent, treat, or manage osteoporosis, a condition that weakens bones, making them fragile and prone to fractures. These drugs work by either slowing bone loss (anti-resorptive drugs) or promoting bone formation (anabolic drugs). Common classes include bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, parathyroid hormone analogs, and monoclonal antibodies. They help reduce fracture risk, improve bone density, and maintain skeletal strength. Prescribed based on factors like age, gender, fracture history, and bone mineral density, osteoporosis drugs are often combined with calcium, vitamin D, and lifestyle changes for optimal bone health and fracture prevention.

Market Dynamics:

Driver:

Rising Geriatric Population

The growing elderly population is a major driver of growth in the osteoporosis medicine market. There is a growing need for efficient treatments as osteoporosis becomes more likely as people age because of a decrease in bone density. The market is growing as a result of older individuals' increased access to and understanding of healthcare. Furthermore, improvements in medication formulations and customized therapies address the unique requirements of senior citizens. The market is expected to increase steadily as governments and healthcare providers place a greater emphasis on bone health, which will benefit patients as well as pharmaceutical businesses.

Restraint:

High Cost of Osteoporosis Drugs

The high cost of osteoporosis drugs significantly hampers market growth by limiting patient access and adherence to treatment. Many individuals, especially in low- and middle-income regions, struggle with affordability, leading to lower demand and increased disease burden. Additionally, high prices strain healthcare budgets and insurance systems, discouraging widespread adoption. This financial barrier restricts market expansion, slows innovation uptake, and forces patients to seek alternative or less effective treatment options.

Opportunity:

Advancements in Drug Development

Advancements in drug development are significantly driving the osteoporosis drugs market by introducing innovative therapies with improved efficacy and safety. Breakthroughs in biologics, monoclonal antibodies, and novel drug formulations are enhancing patient outcomes, reducing fracture risks, and improving bone density. Cutting-edge research in targeted treatments and personalized medicine is expanding the market potential. Additionally, regulatory approvals for next-generation osteoporosis drugs and increased R&D investments are accelerating market growth, offering new hope for millions suffering from osteoporosis worldwide.

Threat:

Side Effects & Safety Concerns

Side effects and safety concerns significantly hinder the growth of the osteoporosis drugs market. Adverse effects such as gastrointestinal issues, cardiovascular risks, and atypical fractures deter patient compliance and physician prescriptions. Safety warnings and regulatory scrutiny further limit drug adoption, impacting sales. Negative publicity and lawsuits also erode consumer trust. These challenges drive demand for alternative treatments, restricting market expansion and affecting pharmaceutical companies' revenue streams.

Covid-19 Impact:

The COVID-19 pandemic disrupted the osteoporosis drugs market by delaying diagnosis and treatment due to healthcare facility closures and reduced patient visits. Supply chain disruptions affected drug availability, while economic uncertainties limited patient affordability. However, increased telemedicine adoption and awareness of bone health during lockdowns supported market recovery. Post-pandemic, the market rebounded as healthcare services resumed, driving demand for osteoporosis treatments.

The parathyroid hormone (PTH) analogs segment is expected to be the largest during the forecast period

The parathyroid hormone (PTH) analogs segment is expected to account for the largest market share during the forecast period due to its ability to stimulate bone formation rather than just slowing bone loss. These drugs, such as teriparatide and abaloparatide, are particularly beneficial for high-risk fracture patients, enhancing bone density and reducing fracture risk. Increased awareness, rising osteoporosis prevalence, and favorable reimbursement policies are further boosting demand. Additionally, ongoing R&D efforts and technological advancements in drug delivery systems are expanding the market presence.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate as hospitals provide advanced diagnostic tools like bone density scans, facilitating early detection and personalized treatment plans. Additionally, specialized healthcare professionals enhance patient education and medication compliance, improving outcomes. The increasing prevalence of osteoporosis, coupled with hospitals' ability to offer comprehensive care, fosters higher drug demand. Moreover, collaborations with pharmaceutical companies support research and innovation, further expanding market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to advancements in drug formulations. Increased awareness, government initiatives, and improved healthcare access further propel market expansion. Pharmaceutical companies are innovating with biologics and anabolic treatments, enhancing patient outcomes. The market positively impacts public health by reducing fracture risks and improving quality of life. With continuous R&D and strategic collaborations, the sector fosters medical advancements, ensuring long-term benefits for patients and healthcare systems.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR due to increasing healthcare investments. Governments and healthcare providers are prioritizing osteoporosis management, leading to improved accessibility to advanced treatments. Innovation in drug formulations and the adoption of biologics are enhancing patient outcomes. Additionally, lifestyle changes and urbanization are increasing the prevalence of osteoporosis, further propelling demand. This market expansion fosters economic growth, job creation, and advancements in pharmaceutical research across the region.

Key players in the market

Some of the key players in Osteoporosis Drugs Market include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Radius Health, Inc., UCB S.A., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Cipla Inc., Daiichi Sankyo Company, Novo Nordisk A/S, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Bayer AG, Johnson & Johnson Services Inc., Sanofi and Bristol-Myers Squibb Company.

Key Developments:

In March 2025, Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007).

In February 2025, Summit Therapeutics Inc. announced a clinical trial collaboration with Pfizer Inc. to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.

In February 2025, Alloy Therapeutics Inc. announced its latest strategic collaboration with Pfizer Inc., to develop a new platform that could enhance Pfizer's ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies.

Drug Classes Covered:

  • Bisphosphonates
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analogues
  • Parathyroid Hormone (PTH) Analogs
  • RANK Ligand (RANKL) Inhibitors
  • Calcitonin
  • Other Drug Classes

Routes of Administration Covered:

  • Oral
  • Injectable

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Clinics
  • Homecare Settings

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Osteoporosis Drugs Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Bisphosphonates
    • 5.2.1 Alendronate
    • 5.2.2 Risedronate
  • 5.3 Selective Estrogen Receptor Modulators (SERMs)
  • 5.4 Parathyroid Hormone-Related Protein (PTHrP) Analogues
  • 5.5 Parathyroid Hormone (PTH) Analogs
  • 5.6 RANK Ligand (RANKL) Inhibitors
  • 5.7 Calcitonin
  • 5.8 Other Drug Classes

6 Global Osteoporosis Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Injectable

7 Global Osteoporosis Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 Global Osteoporosis Drugs Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Homecare Settings

9 Global Osteoporosis Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Amgen Inc.
  • 11.2 Eli Lilly and Company
  • 11.3 Merck & Co., Inc.
  • 11.4 Novartis AG
  • 11.5 Pfizer Inc.
  • 11.6 GlaxoSmithKline plc
  • 11.7 Radius Health, Inc.
  • 11.8 UCB S.A.
  • 11.9 Teva Pharmaceutical Industries Ltd.
  • 11.10 F. Hoffmann-La Roche Ltd
  • 11.11 Cipla Inc.
  • 11.12 Daiichi Sankyo Company
  • 11.13 Novo Nordisk A/S
  • 11.14 Sun Pharmaceutical Industries Ltd.
  • 11.15 AbbVie Inc.
  • 11.16 Bayer AG
  • 11.17 Johnson & Johnson Services Inc.
  • 11.18 Sanofi
  • 11.19 Bristol-Myers Squibb Company

List of Tables

  • Table 1 Global Osteoporosis Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 4 Global Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 5 Global Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 6 Global Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 7 Global Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 8 Global Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 9 Global Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 10 Global Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 11 Global Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 12 Global Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 13 Global Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 14 Global Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 15 Global Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 16 Global Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 17 Global Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 18 Global Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 19 Global Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 21 Global Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 22 Global Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 23 North America Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 24 North America Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 25 North America Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 26 North America Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 27 North America Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 28 North America Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 29 North America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 30 North America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 31 North America Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 32 North America Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 33 North America Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 34 North America Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 35 North America Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 36 North America Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 37 North America Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 38 North America Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 39 North America Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 40 North America Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 41 North America Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 42 North America Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 43 North America Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 44 North America Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 45 Europe Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 46 Europe Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 47 Europe Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 48 Europe Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 49 Europe Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 50 Europe Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 51 Europe Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 52 Europe Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 53 Europe Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 54 Europe Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 55 Europe Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 56 Europe Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 57 Europe Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 58 Europe Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 59 Europe Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 60 Europe Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 61 Europe Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 62 Europe Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 63 Europe Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 64 Europe Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 65 Europe Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 66 Europe Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 67 Asia Pacific Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 68 Asia Pacific Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 69 Asia Pacific Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 70 Asia Pacific Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 71 Asia Pacific Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 72 Asia Pacific Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 73 Asia Pacific Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 74 Asia Pacific Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 75 Asia Pacific Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 76 Asia Pacific Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 77 Asia Pacific Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 78 Asia Pacific Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 79 Asia Pacific Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 80 Asia Pacific Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 81 Asia Pacific Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 82 Asia Pacific Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 83 Asia Pacific Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 84 Asia Pacific Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 85 Asia Pacific Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 86 Asia Pacific Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 87 Asia Pacific Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 88 Asia Pacific Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 89 South America Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 90 South America Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 91 South America Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 92 South America Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 93 South America Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 94 South America Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 95 South America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 96 South America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 97 South America Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 98 South America Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 99 South America Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 100 South America Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 101 South America Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 102 South America Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 103 South America Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 104 South America Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 105 South America Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 106 South America Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 107 South America Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 108 South America Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 109 South America Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 110 South America Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 111 Middle East & Africa Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 112 Middle East & Africa Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 113 Middle East & Africa Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 114 Middle East & Africa Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 115 Middle East & Africa Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 116 Middle East & Africa Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 117 Middle East & Africa Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 118 Middle East & Africa Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 119 Middle East & Africa Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 120 Middle East & Africa Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 121 Middle East & Africa Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 122 Middle East & Africa Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 123 Middle East & Africa Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 124 Middle East & Africa Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 125 Middle East & Africa Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 126 Middle East & Africa Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 127 Middle East & Africa Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 128 Middle East & Africa Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 129 Middle East & Africa Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 130 Middle East & Africa Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 131 Middle East & Africa Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 132 Middle East & Africa Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)